|
 |
European BioPharmaceutical Review
|
| Pharmaceutical companies are facing a new kind of challenge: breakthrough biotech products that are so successful they overwhelm manufacturing capacity. With biological manufacturing set-up costs in the hundreds of millions of dollars per product, it is a tough call to predict market success correctly. Aiming too high in capacity means that costs may never be recovered. On the other hand, with set-up times for new facilities often extending to three or four years, planning capacity too low can mean years of short supply. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Geoff Tomlinson, Principal, and Hannes Kunz, Director of PRTM
Geoff Tomlinson is a Principal in the Life Sciences Practice of global management consultants PRTM. His consulting experience includes work with companies across Europe and the US on supply chain management, marketing and sales initiatives. These engagements have covered a range of industries including pharmaceutical, medical devices and diagnostics, and consumer goods.
Prior to consulting, Geoff worked in management positions for Rank Hovis McDougall in sales, production and quality. He holds a degree in Biological Sciences from Exeter University and has an MBA from Manchester Business School.
Hannes Kunz is a Director in the Life Sciences Practice of global management consultants PRTM. Hannes has led numerous projects with companies across a range of industry sectors, including life sciences. He has extensive experience in facilitating emerging and global companies to deliver value to their customers through their product strategies and product development excellence, e-business, marketing and CRM.
Prior to joining PRTM, Hannes was a Director at a consulting firm with the responsibility for customer relationship management, e-commerce consulting and implementation services for German-speaking countries. Hannes holds degrees in both Law and Economics from the University of Zurich.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
